[go: up one dir, main page]

MX2015005772A - Bencimidazoles triciclicos sustituidos como inhibidores de cinasas. - Google Patents

Bencimidazoles triciclicos sustituidos como inhibidores de cinasas.

Info

Publication number
MX2015005772A
MX2015005772A MX2015005772A MX2015005772A MX2015005772A MX 2015005772 A MX2015005772 A MX 2015005772A MX 2015005772 A MX2015005772 A MX 2015005772A MX 2015005772 A MX2015005772 A MX 2015005772A MX 2015005772 A MX2015005772 A MX 2015005772A
Authority
MX
Mexico
Prior art keywords
substituted tricyclic
compounds
kinase inhibitors
tricyclic benzimidazoles
disclosed
Prior art date
Application number
MX2015005772A
Other languages
English (en)
Other versions
MX363609B (es
Inventor
Tomasz Rzymski
Adrian Zarebski
Agnieszka Dreas
Karolina Osowska
Katarzyna Kucwaj
Joanna Fogt
Marek Cholody
Wojciech Czardybon
Raymond Horvath
Katarzyna Wiklik
Mariusz Milik
Krzysztof Brzózka
Michal Galezowski
Original Assignee
Selvita Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selvita Sa filed Critical Selvita Sa
Publication of MX2015005772A publication Critical patent/MX2015005772A/es
Publication of MX363609B publication Critical patent/MX363609B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se dan a conocer compuestos bencimidazoles tricíclicos sustituidos, tal como se definen en este documento en la fórmula (I), o sales farmacéuticamente aceptables de los mismos. Los compuestos de la invención inhiben de manera selectiva a CDK8 y, por lo tanto, son útiles para tratar enfermedades relacionadas con esta cinasa, especialmente cáncer colorrectal y melanoma, y otras malignidades sólidas y hematológicas, enfermedades autoinmunes y enfermedades inflamatorias. También se dan a conocer procesos para preparar estos compuestos.
MX2015005772A 2012-11-08 2013-11-07 Bencimidazoles triciclicos sustituidos como inhibidores de cinasas. MX363609B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1220157.0A GB201220157D0 (en) 2012-11-08 2012-11-08 Substitute tricyclic benzimidazoles as kinase inhibitors
PCT/EP2013/073311 WO2014072435A1 (en) 2012-11-08 2013-11-07 Substituted tricyclic benzimidazoles as kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2015005772A true MX2015005772A (es) 2015-11-18
MX363609B MX363609B (es) 2019-03-28

Family

ID=47470315

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005772A MX363609B (es) 2012-11-08 2013-11-07 Bencimidazoles triciclicos sustituidos como inhibidores de cinasas.

Country Status (23)

Country Link
US (1) US9745299B2 (es)
EP (1) EP2917217B1 (es)
JP (1) JP6101812B2 (es)
KR (1) KR101812390B1 (es)
CN (1) CN104903321B (es)
AU (1) AU2013343550B2 (es)
BR (1) BR112015010019B1 (es)
CA (1) CA2890643C (es)
CY (1) CY1119084T1 (es)
DK (1) DK2917217T3 (es)
ES (1) ES2628046T3 (es)
GB (1) GB201220157D0 (es)
HR (1) HRP20170802T1 (es)
HU (1) HUE033485T2 (es)
IL (1) IL238693A0 (es)
LT (1) LT2917217T (es)
MX (1) MX363609B (es)
PL (1) PL2917217T3 (es)
PT (1) PT2917217T (es)
RS (1) RS56056B1 (es)
SI (1) SI2917217T1 (es)
SM (1) SMT201700291T1 (es)
WO (1) WO2014072435A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3133075B1 (en) 2014-04-18 2020-12-30 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
JP6977238B2 (ja) * 2015-11-03 2021-12-08 エルユー ライセンス エービーLu License Ab 低増殖性障害の治療のための化合物
CN114921468A (zh) 2017-01-30 2022-08-19 国立大学法人京都大学 新型化合物以及调节性t细胞的制造方法
WO2018159805A1 (ja) 2017-03-03 2018-09-07 国立大学法人京都大学 膵前駆細胞の製造方法
WO2018186366A1 (ja) * 2017-04-03 2018-10-11 京都薬品工業株式会社 新規サイクリン依存性キナーゼ８及び／又は１９阻害剤
JP7285249B2 (ja) 2017-10-02 2023-06-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄｋ８／ｃｄｋ１９阻害剤としての新規な［１，６］ナフチリジン化合物及び誘導体
CA3110436C (en) * 2018-08-24 2023-09-26 Adlai Nortye Biopharma Co., Ltd. High activity sting protein agonist
EP3873896A4 (en) * 2018-12-14 2022-08-31 Jiangsu Hengrui Medicine Co., Ltd. Tricyclic compounds as sting agonists, and preparation methods and medicinal uses thereof
AU2020357983A1 (en) * 2019-10-03 2022-04-21 Dana-Farber Cancer Institute, Inc. Tricyclic kinase inhibitors and uses thereof
CN111349094B (zh) * 2020-04-23 2021-02-02 杭州师范大学 一种6H-咪唑[4,5,1-ij]并喹诺酮及其合成方法和应用
CA3181537A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
TW202237818A (zh) 2020-11-20 2022-10-01 日商千紙鶴治療公司 成熟化劑
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
EP4293105A4 (en) 2021-02-09 2025-07-02 Orizuru Therapeutics Inc MATURING AGENT
CA3214794A1 (en) * 2021-03-25 2022-09-29 University Of South Carolina Cdk8/19 inhibitors for the treatment of cytokine storm
KR20240067089A (ko) 2021-09-27 2024-05-16 고쿠리츠 다이가쿠 호진 교토 다이가쿠 T 세포의 제조 방법
JP2024540292A (ja) 2021-11-09 2024-10-31 エイジャックス セラピューティクス， インコーポレイテッド Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール
WO2023086320A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2
CA3238860A1 (en) 2021-11-24 2023-06-01 Norihisa MIKAMI Pharmaceutical composition for treating or preventing t cell-related disorders
JP7572755B2 (ja) 2021-11-24 2024-10-24 レグセル株式会社 ヒト誘導性制御性ｔ細胞およびその作製方法
JPWO2023182328A1 (es) 2022-03-23 2023-09-28
JPWO2023210578A1 (es) 2022-04-25 2023-11-02
WO2023241627A1 (en) * 2022-06-15 2023-12-21 Insilico Medicine Ip Limited Cdk8/19 dual inhibitors and methods of use thereof
WO2024014497A1 (ja) 2022-07-14 2024-01-18 オリヅルセラピューティクス株式会社 細胞移植用のフィブリンゲルシート
CN119948155A (zh) 2022-09-26 2025-05-06 雷格细胞股份有限公司 含有嵌合抗原受体（car）的诱导性调节性t细胞
KR20250077533A (ko) 2022-09-26 2025-05-30 고쿠리츠 다이가쿠 호진 교토 다이가쿠 T 세포 제조 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2899757B2 (ja) 1989-06-26 1999-06-02 持田製薬株式会社 ジヒドロイミダゾキノリノンオキシムスルホン酸誘導体
US5500423A (en) 1994-09-09 1996-03-19 Hoechst-Roussel Pharmaceuticals Inc. 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolines
PL365080A1 (en) * 2000-08-08 2004-12-27 Sanofi-Aventis Benzimidazole derivatives, preparation and therapeutic use thereof
WO2003051879A1 (en) 2001-12-14 2003-06-26 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
AU2003240742A1 (en) * 2002-06-07 2003-12-22 Altana Pharma Ag 4,5-dihydro-imidazo (4,5,1-ij) quinolin-6-ones derivatives and their use as poly (adp-ribosyl) transferase (parp) inhibitors
RU2008101923A (ru) * 2005-08-05 2009-09-10 Астразенека Аб (Se) Трициклические бензимидазолы и их применение в качестве модуляторов метаботропного глутаматного рецептора
AR056556A1 (es) * 2005-09-30 2007-10-10 Astrazeneca Ab Imidazo(1,2-a)piridina con actividad antiproliferacion celular
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
RU2013138835A (ru) * 2011-02-09 2015-03-20 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения в качестве ингибиторов pi3 киназы

Also Published As

Publication number Publication date
CA2890643C (en) 2018-05-22
KR20150091074A (ko) 2015-08-07
ES2628046T3 (es) 2017-08-01
JP2016503408A (ja) 2016-02-04
EP2917217A1 (en) 2015-09-16
BR112015010019B1 (pt) 2022-08-09
IL238693A0 (en) 2015-06-30
US9745299B2 (en) 2017-08-29
PT2917217T (pt) 2017-06-07
PL2917217T3 (pl) 2017-10-31
CN104903321A (zh) 2015-09-09
US20150274726A1 (en) 2015-10-01
DK2917217T3 (en) 2017-06-19
CY1119084T1 (el) 2018-01-10
WO2014072435A1 (en) 2014-05-15
HRP20170802T1 (hr) 2017-08-11
MX363609B (es) 2019-03-28
KR101812390B1 (ko) 2017-12-26
AU2013343550B2 (en) 2016-09-22
CN104903321B (zh) 2017-10-24
BR112015010019A8 (pt) 2019-09-17
BR112015010019A2 (pt) 2017-07-11
HUE033485T2 (en) 2017-12-28
CA2890643A1 (en) 2014-05-15
LT2917217T (lt) 2017-07-25
GB201220157D0 (en) 2012-12-26
EP2917217B1 (en) 2017-03-08
RS56056B1 (sr) 2017-09-29
AU2013343550A1 (en) 2015-05-14
JP6101812B2 (ja) 2017-03-22
SMT201700291T1 (it) 2017-07-18
SI2917217T1 (sl) 2017-08-31

Similar Documents

Publication Publication Date Title
MX363609B (es) Bencimidazoles triciclicos sustituidos como inhibidores de cinasas.
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
PH12017502141A1 (en) Compounds and their methods of use
MX361815B (es) Compuestos pirazolopirimidinicos como inhibidores de cinasas.
MX344335B (es) Derivados de benzonitrilo como inhibidores de cinasa.
MX2015007057A (es) Derivados novedosos de bencimidazol como inhibidores de cinasas.
MX2020010496A (es) Inhibidores de desmetilasa-1 especifica de lisina.
MX2015007205A (es) Inhibidores de la desmetilasa de histona.
MX362215B (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
MX2012013197A (es) Inhibidores de indazol de cinasa.
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
MX336022B (es) Activadores de pkm2 bicíclicos.
MX357502B (es) Derivados de pirrolotriazinona.
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
MX2016008042A (es) Derivados de imidazopirazinona.
AU2016204389A1 (en) Kinase inhibitors for the treatment of cancer
MX2015012600A (es) Compuestos de tetrahidroisoquinolina-2-il-(quinazolina-4-il) metanona como inhibidores del crecimiento de células cancerígenas.
MX2016000487A (es) Piridina-2-carboxamidas como nematicidas.
NZ712369A (en) 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
PH12013502079A1 (en) New indolinone protein kinase inhibitors
GB201212586D0 (en) Cancer treatment
MY192305A (en) Bipyrazole derivatives as jak inhibitors
GB201016442D0 (en) Novel acridine derivatives
UA110793C2 (uk) Піразолілхіноксалінові інгібітори кінази